KIT and myelodysplastic syndrome: In two cases, (imatinib/KIT for aggressive systemic mastocytosis and imatinib/platelet-derived growth factor receptor B for myelodysplastic syndrome–myeloproliferative disease), the drug approval was supported by only case reports, so data on the interaction were not available.